An interventional study of Modified surgical approach and Cochlear Nucleus CI632 cochlear implant in Deafness With a Cochlear Implant, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Deafness with a site in United States — 19 open to participants now, 22 under way, 1 of them phase 3. Deafness · United States.
Among the 63 studies in Deafness with a site in United States, this one is the 23rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2022, is one of 31 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 60th registered.
161 studies on the registry are indexed under Deafness; 46 are open to participants now.
Browse Deafness studies →19 of the 63 studies in Deafness with a site in United States are open now. Recruiting first, the newest first:
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18–80
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
Craig D. Workman, PhD · Sites in United States
Ages 18–99
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18–85
Eli Lilly and Company · Sites in United States, Canada, Taiwan and 1 more country
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Deafness studies recruiting now, 11 (37%) set no upper age limit and 10 (33%) stop at 75 or younger; 19 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 1997; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 42 across 107 interventional studies indexed under Deafness.
Median enrollment 41 across the 44 interventional studies, 249 across the 19 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 63 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 5 studies filed under Deafness — fewer than ten, so there is no comparison to draw.
9 of the studies in Deafness with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT06960616Massachusetts Eye and Ear InfirmaryImproving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy | 2026-11-26 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT05203302NYU Langone HealthNovel Coding Strategies for Children With Cochlear Implants | 2027-01-01 |
| NCT06901674NYU Langone HealthStimulating the Cochlear Apex Without Longer Electrodes | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies in Deafness with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The most common cochlear implant intervention provides an electrode array that stimulates less than half of the length of the cochlea, leaving the regions which represent lower frequencies in the normally functioning ear unstimulated. Providing stimulation over the entire cochlea has the potential to improve speech understanding, sound quality, as well as spectral and temporal representation. Increasing the length of the electrode array to cover a greater portion of the cochlea has many potential issues, including increased damage to the cochlea and probability of incomplete insertions. In this study, a new technique is being investigated that allows stimulation across the entire cochlear extent without increasing the length of the electrode array. The purpose of this study is to evaluate the benefit of the new technique on speech understanding outcomes. Additionally, the study will investigate the new configuration to explore how the auditory system encodes temporal and spectral information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this group will have already received a cochlear implant using the new approach or be receiving a cochlear implant with the new approach.
Procedure: Modified surgical approach · Device: Cochlear Nucleus CI632 cochlear implant
Participants in this group have received a cochlear implant with the typical ground electrode placement.
Device: Cochlear Nucleus CI632 cochlear implant
An electrode typically placed under the temporalis muscle will be placed into the cochlear helicotrema instead.
Cochlear implant (CI) system where stimulation from one of the intracochear electrodes is grounded via one of two (or both) extra cochlear electrodes in the device.
Upper Limit of Rate Pitch Perception for Cochlear Implant Stimuli
The upper limit of rate pitch perception will be evaluated for Apex-monopolar (MP), 22-Apex, 22-MP, and 11-MP cochlear implant stimuli using a 3-up 1-down 2-interval forced-choice adaptive task. The task measures the highest modulation frequency perceived as a lower pitch compared to a rate 5 semitones higher. A series of 750-ms, 5000-pps pulse trains with 100% amplitude modulation will be presented at a loudness-balanced most-comfortable level. The upper limit will be estimated from the average modulation frequency of the last 6 reversals across 10 trials per stimulation site.
Time frame: Month 12
Mean pitch rank
Pitch-ranking will be done using a 2-interval forced-choice protocol in which the pitch of a newly selected stimulus is ranked relative to the stimulus in the middle of a pitch-rank order list. Depending on the ranked pitch direction, this stimulus is repositioned in the pitch-rank order list and ranked against a neighboring stimulus until the correct position in the list is determined. This process repeated until all stimuli are successfully pitch ranked. A complete set of pitch ranks are measured 10 times allowing for the calculation of a mean rank and 95% confidence interval for the rank of each interval.
Time frame: Month 12
Percentage of Consonant-Nucleus-Consonant (CNC) words correctly repeated
Speech perception will be assessed using CNC word lists, a common method for evaluating monosyllabic word recognition. The CNC Monosyllabic Word Test includes 10 lists of 50 words. The word test score range typically used is between 10% and 60% correct in the ear to be implanted, and equal to or better than that ear in the contralateral ear, but not better than 80% correct.
Time frame: Month 12
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to:David.landsberger@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: Requests should be directed to David.landsberger@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
Started Aug 2022 (actual). Primary completion is estimated for Jan 2027, 53 months after the start.
Of 50 non-industry interventional studies with no phase under Deafness, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20. This study's planned 53 months is above that.
Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.